Sofia Paul

3.7k total citations · 1 hit paper
24 papers, 2.7k citations indexed

About

Sofia Paul is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sofia Paul has authored 24 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Sofia Paul's work include Estrogen and related hormone effects (6 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Sofia Paul is often cited by papers focused on Estrogen and related hormone effects (6 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Sofia Paul collaborates with scholars based in United States, Switzerland and Canada. Sofia Paul's co-authors include Frances A. Shepherd, Nasser H. Hanna, Paul A. Bunn, U. Gatzemeier, Joachim von Pawel, Lawrence Einhorn, Paolo Paoletti, Jose R. Pereira, Thomas Chang Yao Tsao and Miklos Pless and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Sofia Paul

23 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Nasser H. Hanna, Frances A. Shepherd et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Sofia Paul

Since Specialization

Citations

This map shows the geographic impact of Sofia Paul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofia Paul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofia Paul more than expected).

Fields of papers citing papers by Sofia Paul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofia Paul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofia Paul. The network helps show where Sofia Paul may publish in the future.

Co-authorship network of co-authors of Sofia Paul

This figure shows the co-authorship network connecting the top 25 collaborators of Sofia Paul. A scholar is included among the top collaborators of Sofia Paul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofia Paul. Sofia Paul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC). 2023 ·Journal of Clinical Oncology ·Dejan Juric, Debra L. Richardson, Babar Bashir, Manish Sharma, Kyriakos P. Papadopoulos, (unknown), Graeme Hodgson, (unknown), Sofia Paul, Terence Hall, David A. Roth, Michael T. Kelly, (unknown), Virginia M. Klimek	2
2	Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy 2023 ·Journal of Clinical Oncology ·Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo de Marinis, Joachim von Pawel, U. Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Müller, (unknown), Christopher E. Desch, Klára Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn	8
3	Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel. 2023 ·Journal of Clinical Oncology ·Babar Bashir, Manish Sharma, Dejan Juric, Kyriakos P. Papadopoulos, Erika Hamilton, Debra L. Richardson, Geoffrey I. Shapiro, Vaibhav Sahai, Niharika B. Mettu, Zev A. Wainberg, Olatunji B. Alese, Tomislav Dragovich, Graeme Hodgson, (unknown), Terence Hall, Sofia Paul, David A. Roth, Michael T. Kelly, (unknown), Virginia M. Klimek	2
4	Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer. 2022 ·Journal of Clinical Oncology ·Manish Sharma, Babar Bashir, Dejan Juric, Erika Hamilton, Kyriakos P. Papadopoulos, Susanna V. Ulahannan, Geoffrey I. Shapiro, Vaibhav Sahai, Niharika B. Mettu, Monica Mita, Mehmet Akce, Jessica J. Tao, Graeme Hodgson, Nan Rosemary Ke, Susan A. Henry, Sofia Paul, (unknown), Catherine K. Madigan, David A. Roth, Virginia M. Klimek	3
5	MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Malin Hultcrantz, Larry D. Anderson, Faiz Anwer, Cristina Gasparetto, Mehmet H. Kocoglu, Eben I. Lichtman, Clifton C. Mo, Rubén Niesvizky, Eric Lewis, Hong Li, Sofia Paul, Stephanie Petrone, Jonathan L. Kaufman	0
6	DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM). 2020 ·Journal of Clinical Oncology ·Paul G. Richardson, Swethajit Biswas, Beata Holkova, Nicola Jackson, (unknown), Sofia Paul, Geraldine Ferron‐Brady, Anne Yeakey, (unknown), Rocío Montes de, Christoph M. Ahlers, Marc Ballas, Elaine Paul, Ira Gupta, Joanna Opalińska, Katarina Luptakova	4
7	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors 2013 ·Investigational New Drugs ·Sunil Sharma, Joachim Beck, Monica Mita, Sofia Paul, Margaret M. Woo, Margaret Squier, Brian Gadbaw, H. Miles Prince	29
8	Characteristics of Thrombocytopenia in Patients Treated with Oral Panobinostat (LBH589). 2009 ·Blood ·(unknown), Jing Hu, Sofia Paul, Joanne Schindler, Margaret M. Woo, Stan Spence, Samit Hirawat, Harald Weber	5
9	Population Pharmacokinetics of Panobinostat (LBH589) in Patients with Advanced Solid Tumors and Hematologic Malignancies Following Intravenous and Oral Administration. 2009 ·Blood ·(unknown), Margaret M. Woo, Harald Weber, Samit Hirawat, Sofia Paul, Joanne Schindler, Roland Fisch	2
10	QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589). 2009 ·Blood ·Harald Weber, Feng Tai, Sofia Paul, Joanne Schindler, Margaret M. Woo, Stan Spence, Jennifer Marlowe, (unknown)	5
11	The type I error and power of non‐parametric logrank and Wilcoxon tests with adjustment for covariates—A simulation study 2008 ·Statistics in Medicine ·Honghua Jiang, James T. Symanowski, Sofia Paul, Yongming Qu, Anthony J. Zagar, Shengyan Hong	17
12	Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis 2007 ·Journal of Thoracic Oncology ·Jean-Louis Pujol, Sofia Paul, Nadia Chouaki, Patrick Peterson, (unknown), Donald A. Berry, Marc Salzberg	47
13	Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer 2006 ·Journal of Clinical Oncology ·Glen J. Weiss, Corey J. Langer, Rafael Rosell, Nasser H. Hanna, Frances A. Shepherd, Lawrence H. Einhorn, Binh Thanh Nguyen, Sofia Paul, (unknown), Paul A. Bunn, Karen Kelly	120
14	O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC) 2003 ·Lung Cancer ·Nasser H. Hanna, Sofia Paul, (unknown), Frank V. Fossella, Marc Salzberg, Thomas Mueller, Frances A. Shepherd, Binh Nguyen, L. Kayitalire, (unknown), Lawrence Einhorn	5
15	Design and methods of the Raloxifene Use for The Heart (RUTH) study 2001 ·The American Journal of Cardiology ·Lori Mosca, Elizabeth Barrett‐Connor, Nanette K. Wenger, Peter Collins, Deborah Grady, Marcel Kornitzer, E Moscarelli, Sofia Paul, Theressa J. Wright, Jeffrey D. Helterbrand, Pamela W. Anderson	129
16	Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women 2001 ·Maturitas ·Pamela W. Anderson, David A. Cox, Andreas Sashegyi, Sofia Paul, Sheryl L. Silfen, Brian W. Walsh	15
17	The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled Trial1 2000 ·The Journal of Clinical Endocrinology & Metabolism ·Brian W. Walsh, Sofia Paul, Robert A. Wild, Robert A. Dean, Russell P. Tracy, David A. Cox, Pamela W. Anderson	285
18	Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles1 1998 ·The Journal of Clinical Endocrinology & Metabolism ·Valerie L. Baker, Michael Draper, Sofia Paul, (unknown), Michael D. Glant, Jan L. Shifren, Robert B. Jaffe	86
19	Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women With Regular Menstrual Cycles 1998 ·Obstetrical & Gynecological Survey ·Valerie L. Baker, Michael Draper, Sofia Paul, (unknown), Michael D. Glant, Jan L. Shifren, Robert B. Jaffe	3
20	Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women 1998 ·Primary Care Update for OB/GYNS ·J. E. Glusman, William J. Huster, Sofia Paul	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact